{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:00:25Z","timestamp":1793754025761,"version":"4.6.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:00:00Z","timestamp":1522627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1093\/cid\/ciy145","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T08:39:12Z","timestamp":1521707952000},"page":"504-512","source":"Crossref","is-referenced-by-count":171,"title":["Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation"],"prefix":"10.1093","volume":"67","author":[{"given":"Stephanie N","family":"Taylor","sequence":"first","affiliation":[{"name":"Section of Infectious Disease, Louisiana State University Health Sciences Center, New Orleans"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Morris","sequence":"additional","affiliation":[{"name":"Desert AIDS Project, Palm Springs, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann K","family":"Avery","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, MetroHealth Medical Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A","family":"Workowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Emory University Department of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron E","family":"Batteiger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney A","family":"Tiffany","sequence":"additional","affiliation":[{"name":"Research & Development, GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R","family":"Perry","sequence":"additional","affiliation":[{"name":"Research & Development, GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"Research & Development, GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E","family":"Scangarella-Oman","sequence":"additional","affiliation":[{"name":"Research & Development, GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hossain","sequence":"additional","affiliation":[{"name":"Research & Development, GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne F","family":"Dumont","sequence":"additional","affiliation":[{"name":"Research & Development, GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,2]]},"reference":[{"key":"key\n\t\t\t\t20180801023005_CIT0001","volume-title":"WHO guidelines for the treatment of Neisseria gonorrhoeae","author":"World Health Organization","year":"2016"},{"key":"key\n\t\t\t\t20180801023005_CIT0002","volume-title":"Sexually transmitted diseases surveillance 2016","author":"Centers for Disease Control and Prevention","year":"2017"},{"key":"key\n\t\t\t\t20180801023005_CIT0003","volume-title":"Annual epidemiological report 2016\u2013gonorrhea","author":"European Centre for Disease Prevention and Control","year":"2016"},{"key":"key\n\t\t\t\t20180801023005_CIT0004","first-page":"627","article-title":"Gonococcal infections in the adult","volume-title":"Sexually transmitted diseases","author":"Hook","year":"2008","edition":"4th ed"},{"key":"key\n\t\t\t\t20180801023005_CIT0005","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180801023005_CIT0006","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11908-011-0169-9","article-title":"Gonococcal resistance: are cephalosporins next","volume":"13","author":"Kirkcaldy","year":"2011","journal-title":"Curr Infect Dis Rep"},{"key":"key\n\t\t\t\t20180801023005_CIT0007","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1128\/AAC.05760-11","article-title":"High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure","volume":"56","author":"Unemo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180801023005_CIT0008","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJMp1112456","article-title":"The emerging threat of untreatable gonococcal infection","volume":"366","author":"Bolan","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801023005_CIT0009","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1128\/AAC.00325-11","article-title":"Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: Detailed characterization of the first strain with high-level resistance to ceftriaxone","volume":"55","author":"Ohnishi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180801023005_CIT0010","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2217\/fmb.12.117","article-title":"Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea","volume":"7","author":"Unemo","year":"2012","journal-title":"Future Microbiol"},{"key":"key\n\t\t\t\t20180801023005_CIT0011","volume-title":"Antibiotic resistance threats in the United States, 2013","author":"Centers for Disease Control and Prevention","year":"2013"},{"key":"key\n\t\t\t\t20180801023005_CIT0012","volume-title":"Gonorrhea treatment guidelines: revised guidelines to preserve last effective treatment option","author":"Centers for Disease Control and Prevention","year":"2013"},{"key":"key\n\t\t\t\t20180801023005_CIT0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6507a1","article-title":"Neisseria gonorrhoeae antimicrobial susceptibility surveillance\u2014the Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014","volume":"65","author":"Kirkcaldy","year":"2016","journal-title":"MMWR Surveill Summ"},{"key":"key\n\t\t\t\t20180801023005_CIT0014","doi-asserted-by":"crossref","first-page":"e1002366","DOI":"10.1371\/journal.pmed.1002366","article-title":"Multidrug-resistant gonorrhea: a research and development roadmap to discover new medicines","volume":"14","author":"Alirol","year":"2017","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20180801023005_CIT0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0956462412472837","article-title":"2012 European guideline on the diagnosis and treatment of gonorrhoea in adults","volume":"24","author":"Bignell","year":"2013","journal-title":"Int J STD AIDS"},{"key":"key\n\t\t\t\t20180801023005_CIT0016","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20180801023005_CIT0017","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1186\/s12879-017-2707-z","article-title":"Overall low extended-spectrum cephalosporin resistance but high azithromycin resistance in Neisseria gonorrhoeae in 24 European countries, 2015","volume":"17","author":"Cole","year":"2017","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180801023005_CIT0018","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/cid\/cix485","article-title":"Cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance and decreased ceftriaxone susceptibility, Hawaii, 2016","volume":"65","author":"Katz","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180801023005_CIT0019","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/OLQ.0b013e3182685d2b","article-title":"Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011)","volume":"39","author":"Soge","year":"2012","journal-title":"Sex Transm Dis"},{"key":"key\n\t\t\t\t20180801023005_CIT0020","doi-asserted-by":"crossref","DOI":"10.3201\/eid2402.171756","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae, Canada, 2017","author":"Lefebvre","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20180801023005_CIT0021","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/cid\/civ478","article-title":"A phase 2 trial of oral solithromycin 1200 mg or 1000 mg as single-dose oral therapy for uncomplicated gonorrhea","volume":"61","author":"Hook","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180801023005_CIT0022","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/cid\/ciu521","article-title":"The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea","volume":"59","author":"Kirkcaldy","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180801023005_CIT0023","first-page":"S147","article-title":"A phase II trial of single-dose oral ETX0914 (AZD0914) for treatment of uncomplicated urogenital gonorrhea [abstract 5B5]. 2016 STD Prevention Conference (Atlanta)","volume":"43","author":"Taylor","year":"2016","journal-title":"Sex Transm Dis"},{"key":"key\n\t\t\t\t20180801023005_CIT0024","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180801023005_CIT0025","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02820-15","article-title":"In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180801023005_CIT0026","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/00498254.2015.1112933","article-title":"The metabolism and disposition of GSK2140944 in healthy human subjects","volume":"46","author":"Negash","year":"2016","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t20180801023005_CIT0027","unstructured":"Tiffany CA , HossainM, McDonaldM, et al Safety and pharmacokinetics of single escalating oral doses of GSK2140944, a novel bacterial topoisomerase inhibitor [abstract F-1218]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Denver). American Society for Microbiology, 2013. Available at: http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=5a00e178-5200-4888-bd14-54df807b1a86&cKey=e2bf6c2c-ce55-4645-97c2-085165aba0d2&mKey=7dd36e88-52c3-4ff1-a5df-1d00766558b8. Accessed 20 July 2017."},{"key":"key\n\t\t\t\t20180801023005_CIT0028","unstructured":"Tiffany CA , HossainM, McDonaldM, LermanS, DumontEF. Safety and pharmacokinetics of single escalating IV doses of GSK2140944, a novel bacterial topoisomerase inhibitor [abstract F-277]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2014. Available at: http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=018d4f7b-adbb-4284-a1a7-bd3dacc88b1c&cKey=65c91e81-a211-4b2c-ba1d-fccfd39dd938&mKey=5d6b1802-e453-486b-bcbb-b11d1182d8bb. Accessed 20 July 2017."},{"key":"key\n\t\t\t\t20180801023005_CIT0029","unstructured":"Tiffany CA , HossainM, McDonaldM, LermanS, DumontEF. Safety and pharmacokinetics of repeat escalating IV doses of GSK2140944, a novel bacterial topoisomerase inhibitor [abstract F-278]. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2014. Available at: http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=018d4f7b-adbb-4284-a1a7-bd3dacc88b1c&cKey=22532b0d-62d2-4c64-b47c-2856992644d4&mKey=5d6b1802-e453-486b-bcbb-b11d1182d8bb. Accessed 20 July 2017."},{"key":"key\n\t\t\t\t20180801023005_CIT0030","doi-asserted-by":"crossref","first-page":"e02047","DOI":"10.1128\/AAC.02047-16","article-title":"In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae","volume":"61","author":"Farrell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180801023005_CIT0031","first-page":"A84","article-title":"P2.38 Microbiological analysis from a phase ii study in adults evaluating single doses of gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea caused by Neisseria gonorrhoeae","volume":"93","author":"Scangarella-Oman","year":"2017","journal-title":"Sex Transm Infect"},{"key":"key\n\t\t\t\t20180801023005_CIT0032","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"key\n\t\t\t\t20180801023005_CIT0033","doi-asserted-by":"crossref","first-page":"e02385","DOI":"10.1128\/AAC.02385-16","article-title":"A phase I, randomized, double-blinded, placebo- and moxifloxacin-controlled, four-period crossover study to evaluate the effect of gepotidacin on cardiac conduction as assessed by 12-lead electrocardiogram in healthy volunteers","volume":"61","author":"Hossain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180801023005_CIT0034","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7326\/0003-4819-139-3-200308050-00007","article-title":"Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States","volume":"139","author":"Lyss","year":"2003","journal-title":"Ann Intern Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/4\/504\/25368298\/ciy145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T03:55:37Z","timestamp":1570938937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/4\/504\/4958398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,2]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,2]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy145","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8,15]]},"published":{"date-parts":[[2018,4,2]]}}}